{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:30:53Z","timestamp":1793997053480,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1245\/s10434-019-07830-w","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T15:05:17Z","timestamp":1568819117000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)"],"prefix":"10.1245","volume":"27","author":[{"given":"Danielle M.","family":"Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"13","key":"7830_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa060992","volume":"355","author":"DL Morton","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. New Engl J Med. 2006;355(13):1307\u20131317.","journal-title":"New Engl J Med."},{"issue":"7","key":"7830_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. New Engl J Med. 2014;370(7):599\u2013609.","journal-title":"New Engl J Med."},{"issue":"6","key":"7830_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u2013767.","journal-title":"Lancet Oncol."},{"issue":"23","key":"7830_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u20132222.","journal-title":"N Engl J Med."},{"issue":"19","key":"7830_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u20131855.","journal-title":"N Engl J Med."},{"issue":"19","key":"7830_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u20131823.","journal-title":"N Engl J Med."},{"issue":"19","key":"7830_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u20131835.","journal-title":"N Engl J Med."},{"key":"7830_CR8","first-page":"869","volume":"140","author":"HM Snow","year":"1982","unstructured":"Snow HM. Melanotic cancerous disease. Lancet. 1982;140:869\u2013922.","journal-title":"Lancet."},{"issue":"2","key":"7830_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10434-000-0087-9","volume":"7","author":"Charles M. Balch","year":"2000","unstructured":"Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0\u00a0mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7(2):87\u201397.","journal-title":"Annals of Surgical Oncology"},{"issue":"9105","key":"7830_CR10","first-page":"793","volume":"351","author":"N Cascinelli","year":"1998","unstructured":"Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793\u2013796.","journal-title":"WHO Melanoma Programme. Lancet."},{"issue":"11","key":"7830_CR11","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2","volume":"49","author":"U Veronesi","year":"1982","unstructured":"Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49(11):2420\u20132430.","journal-title":"Cancer."},{"issue":"9","key":"7830_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0025-6196(12)62768-2","volume":"61","author":"FH Sim","year":"1986","unstructured":"Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61(9):697\u2013705.","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"7830_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392\u2013399.","journal-title":"Arch Surg."},{"issue":"7","key":"7830_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/sim.4131","volume":"30","author":"LL Altstein","year":"2011","unstructured":"Altstein LL, Li G, Elashoff RM. A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Stat Med. 2011;30(7):709\u2013717.","journal-title":"Stat Med."},{"issue":"12","key":"7830_CR15","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","volume":"17","author":"MB Faries","year":"2010","unstructured":"Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17(12):3324\u20133329.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"7830_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jamcollsurg.2017.05.013","volume":"225","author":"DW Nelson","year":"2017","unstructured":"Nelson DW, Stern S, Elashoff DE, et al. Impact of time between diagnosis and SLNB on outcomes in cutaneous melanoma. J Am Coll Surg. 2017;225(2):302\u2013311.","journal-title":"J Am Coll Surg."},{"issue":"8","key":"7830_CR17","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","volume":"19","author":"JH Howard","year":"2012","unstructured":"Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547\u20132555.","journal-title":"Ann Surg Oncol."},{"key":"7830_CR18","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u2013492.","DOI":"10.3322\/caac.21409"},{"issue":"36","key":"7830_CR19","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u20136206.","journal-title":"J Clin Oncol."},{"issue":"4","key":"7830_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"Daniel G. Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367\u2013402.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"2","key":"7830_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","volume":"25","author":"SL Wong","year":"2018","unstructured":"Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018;25(2):356\u2013377.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"7830_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jamasurg.2013.3044","volume":"148","author":"AM Leung","year":"2013","unstructured":"Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg. 2013;148(9):879\u2013884.","journal-title":"JAMA Surg."},{"issue":"1","key":"7830_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1245\/s10434-008-0187-5","volume":"16","author":"C Ariyan","year":"2009","unstructured":"Ariyan C, Brady MS, Gonen M, Busam K, Coit D. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(1):186\u2013190.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07830-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:25:12Z","timestamp":1600305912000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07830-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07830-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Bello has worked as a consultant for survivornet. Dr. Faries serves on advisory boards for Novartis, Pulse Bioscience, and Bristol-Myers Squibb. He is a consultant for Delcath Systems.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}